Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) EBT Margin (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed EBT Margin for 9 consecutive years, with 1157.31% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 107630.0% to 1157.31% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.03% through Dec 2025, down 6413.0% year-over-year, with the annual reading at 1.03% for FY2025, 6328.0% down from the prior year.
  • EBT Margin hit 1157.31% in Q4 2025 for Protagonist Therapeutics, up from 834.87% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 1157.31% in Q4 2025 to a low of 4551.0% in Q2 2022.
  • Historically, EBT Margin has averaged 442.83% across 5 years, with a median of 205.03% in 2022.
  • Biggest YoY gain for EBT Margin was 136583bps in 2021; the steepest drop was -1011383bps in 2021.
  • Year by year, EBT Margin stood at 1031.57% in 2021, then plummeted by -103bps to 30.46% in 2022, then surged by 997bps to 273.35% in 2023, then tumbled by -70bps to 81.01% in 2024, then soared by 1329bps to 1157.31% in 2025.
  • Business Quant data shows EBT Margin for PTGX at 1157.31% in Q4 2025, 834.87% in Q3 2025, and 623.86% in Q2 2025.